NCT02979535View on ClinicalTrials.gov

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

PHASE3CompletedINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

November 16, 2016

Primary Completion Date

March 25, 2019

Study Completion Date

March 25, 2019

Conditions
Dengue FeverDengue Hemorrhagic FeverHuman Papillomavirus Disease
Interventions
BIOLOGICAL

CYD Dengue Vaccine

0.5 mL, SC at Day 0, Months 6 and 12

BIOLOGICAL

CYD Dengue Vaccine

0.5 mL, SC at Months 1, 7, and 13

BIOLOGICAL

Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant

0.5 mL, IM at Day 0 and Month 6

BIOLOGICAL

Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant

0.5 mL, IM at Day 0 and Month 6

Trial Locations (1)

Unknown

Mexico City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02979535 - Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® | Biotech Hunter | Biotech Hunter